-The Hindustan Times The drafting of the National Health Policy (NHP) 2015 is an extremely welcome development. The government's decision to announce Health as a Right is a huge advance. Public health spending as a share of GDP barely rose from 0.9 to 1.1% under the previous government. Governments in rich countries have been spending 5% of GDP on health for decades. Why should we welcome the NHP 2015? Countries with...

-Economic and Political Weekly The key to improving the quality of healthcare services in India and reducing costs at the same time can be found by enacting legislation which lays down minimum standards of patient care. In the absence of such standards and the reluctance of health insurance companies to standardise either price or quality, healthcare services continue to be expensive and of doubtful quality. Developing standards of patient care by...

-Vikalp Once again, India is under pressure from the US to revise its patent law. Anyone familiar with the activities of the United States Trade Representatives (USTR) would know that this is nothing new. It has been among the USTR's primary mandates to use trade restrictions in order to persuade (to put it mildly) countries to strengthen their IPR laws. There is, however, a qualitative difference between the actions it has...

-The Hindu A statistically faulty focus on rape has led to a misdiagnosis and a worsening of India's real problem: women's autonomy The recently reported rape of a young woman in a taxi in Delhi has brought back attention to India's sexual violence problem. The spotlight has been on the country since the horrific rape of a young woman aboard a bus in December 2012, an attack that killed her. The beginning...

-The Telegraph Regulators in several European countries are suspending marketing approval for 25 generic drugs because of concerns over the quality of data from human studies conducted by an Indian contract research company, a French medical safety agency said on Friday. Drug regulators in Belgium, France, Germany and Luxembourg have decided to suspend the marketing authorisation for the generic drugs after they discovered "irregularities" in documents relating to human studies conducted by...